Results 151 to 160 of about 16,167 (200)

Mineralocorticoid receptor antagonists in adults with resistant hypertension and obstructive sleep apnoea. [PDF]

Aust Prescr
europepmc   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis. [PDF]

J Hum Hypertens
Shah SS, Zhang J, Gwini SM, Young MJ, Fuller PJ, Yang J.   +5 more
europepmc   +1 more source

Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists. [PDF]

J Clin Invest
Abedini A, Sánchez-Navaro A, Wu J, Klötzer KA, Ma Z, Poudel B, Doke T, Balzer MS, Frederick J, Cernecka H, Liu H, Liang X, Vitale S, Kolkhof P, Susztak K.   +14 more
europepmc   +1 more source

Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease.

Clin J Am Soc Nephrol
Zachariah T, Radhakrishnan J.
europepmc   +1 more source

Novel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, and Mineralocorticoid Receptor Antagonists in Stable Patients With Heart Failure With Reduced Ejection Fraction (NovCon Sequencing Study): Protocol for a Randomized Controlled Trial.

JMIR Res Protoc
Karamchand S, Chipamaunga T, Naidoo P, Naidoo K, Rambiritch V, Ho K, Chilton R, McMahon K, Leisegang R, Weich H, Hassan K.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mineralocorticoid receptor antagonists

2023
Abstract Hypertension, post-myocardial infarction, and heart failure are the cardiovascular clinical syndromes where mineralocorticoid receptor antagonists (MRAs) have shown a beneficial effect. Most guidelines, while recommending MRAs, do not make a clear recommendation as to which MRAs should be used, how doses should be titrated, or ...
Bertram Pitt, João Pedro Ferreira, Faiez Zannad   +2 more
openaire   +1 more source

Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

Current Hypertension Reports, 2020
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta, Eiichiro, Yamamoto, Kenichi, Tsujita   +2 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists

Current Hypertension Reports, 2007
With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of
Parthasarathy, Hari Krishnan, MacDonald, Thomas M.   +1 more
openaire   +3 more sources

Mineralocorticoid receptor antagonists

2022
Abstract This chapter studies the use of aldosterone antagonists, also known as mineralocorticoid receptor antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction—now called heart failure with reduced ejection fraction (HFrEF)—have been very ...
S. Rekhraj, Ben. R. Szwejkowski, Allan D. Struthers   +2 more
openaire   +1 more source